Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma


Abstract

Background – Recent in vitro and in vivo studies in animals have suggested that ambient oxygen tension may influence airway responsiveness to bronchoconstrictor stimuli. These observations may have relevance to the management of acute exacerbations of asthma. The present studies were designed to examine the influence of inspired oxygen tension (FiO₂ 1.0, 0.21, 0.15) on methacholine induced bronchoconstriction in patients with asthma.

Methods – In a dual study two groups of asthmatic patients performed methacholine inhalation challenges breathing either air (FiO₂ 0.21) or a hypoxic gas mixture (FiO₂ 0.15) in study 1 and air (FiO₂ 0.21) or hyperoxia (FiO₂ 1.0) in study 2. The gases were administered through a closed breathing circuit in a randomised double blind fashion. The PC₂₀ values (dose of methacholine causing a 20% fall in forced expiratory volume in one second (FEV₁)) were calculated after each methacholine challenge by linear interpolation from the logarithmic dose response curve. Plasma catecholamine levels were measured before and after methacholine challenges as well as heart rate, oxygen saturation, and percentage end tidal carbon dioxide levels.

Results – The geometric mean PC₂₀ value for methacholine was significantly lower on the hypoxic study day than on the normoxic day in study 1 (mean difference in PC₂₀ values 2.88 mg/ml (95% CI 1.4 to 5.3); p<0.05), but there was no significant difference in the geometric mean PC₂₀ value for methacholine between the hyperoxic and normoxic study days in study 2 (mean difference in PC₂₀ values 1.45 mg/ml (95% CI 0.83 to 2.51)).

Conclusions – Acute hypoxia potentiates methacholine induced bronchoconstriction and acute hyperoxia has no effect in mild to moderate patients with stable asthma.

(Thorax 1997;52:453–457)

Keywords: hyperoxia, hypoxia, bronchoconstriction, methacholine, asthma.

Little is known about the effect of acute alterations in oxygen tension on the responsiveness of the airways to bronchoconstrictor stimuli. Recent in vitro and in vivo studies in animals suggest that hypoxia potentiates and hyperoxia attenuates the airway constrictor response to certain stimuli. Similar in vivo studies in man, however, have produced conflicting findings. If airway responsiveness is increased by a fall in oxygen tension during acute exacerbations of asthma, then the administration of high concentrations of inspired oxygen may act to reduce this effect.

The present studies were designed to investigate the effect of acute hypoxia and hyperoxia on methacholine induced bronchoconstriction in patients with asthma.

Methods

Study 1

Eleven mild asthmatic patients (five men) of mean (SD) age 42 (12) years were recruited into the study (table 1). All were receiving inhaled β₂ agonists as required, 10 were receiving regular inhaled corticosteroids, two were taking regular inhaled salmeterol, and one a long acting oral theophylline.

Study 2

Fourteen adult mild asthmatic patients (five men) of mean (SD) age 36 (9.2) years were recruited into the study (table 1). All were receiving inhaled β₂ agonists on an as required basis, 10 were receiving regular inhaled corticosteroids, two were taking regular oral theophyllines, and one inhaled salmeterol.

In both studies on each study day inhaled β₂ agonists were discontinued for eight hours, salmeterol for 24 hours, and oral theophyllines for 48 hours prior to attendance. Patients were asked to continue their inhaled corticosteroids as usual. They were asked to refrain from caffeine containing products for eight hours before each study day. All patients had been

Table 1  Patient characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Mean (SD) age (years)</th>
<th>Mean (SD) FEV₁ (%)</th>
<th>% predicted</th>
<th>Geometric mean (range) PC₂₀, methacholine (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>11</td>
<td>42 (12)</td>
<td>2.76 (0.49)</td>
<td>86 (7.7)</td>
<td>1.13 (0.04–7.90)</td>
</tr>
<tr>
<td>Study 2</td>
<td>14</td>
<td>36 (9.2)</td>
<td>2.80 (0.60)</td>
<td>90 (8.6)</td>
<td>0.84 (0.04–7.90)</td>
</tr>
</tbody>
</table>

FEV₁ = forced expiratory volume in one second; PC₂₀ methacholine = concentration of methacholine provoking a fall in FEV₁ of 20%.
stable for a period of two months before entry into the study with no significant change in their asthma symptoms or medication. All patients gave informed consent to the studies which had the approval of the West ethics committee.

STUDY DESIGN
For both study 1 and study 2 patients attended the laboratory on three separate days at approximately the same time each day. Patients were excluded from the study if there was any significant change in their asthma symptoms or medication between visits. The maximum period between each visit was seven days. During the initial screening visit each patient underwent a methacholine inhalation challenge test to determine the PC_{20} — that is, the concentration of methacholine causing a 20% fall in forced expiratory volume in one second (FEV₁). On the subsequent two days, after 30 minutes of supine rest, the patients were commenced on a closed breathing circuit. Following a 10 minute run-in period breathing air (F_{iO₂} 0.21) baseline measurements of FEV₁, respiratory rate (RR), heart rate (HR), oxygen saturation (S_{AO₂}%), inspired oxygen and carbon dioxide levels (insp O₂%, insp CO₂%), and expired oxygen and carbon dioxide levels (PETO₂%, PETCO₂%) were made. Venous blood was also taken for assay of plasma catecholamines.

In study 1 patients then received either air (F_{iO₂} 0.21) or a hypoxic gas mixture (F_{iO₂} 0.15) and in study 2 either air (F_{iO₂} 0.21) or oxygen (F_{iO₂} 1.0) for the remainder of the study day. All gases were administered in a randomised double blind manner by a second person obscured from the vision of both the patient and the doctor administering the methacholine challenge. The methacholine inhalation challenge was performed 10 minutes after starting the study gas. All measurements, except venous blood sampling, were repeated before commencing the methacholine inhalation challenge. The study day was terminated when a PC_{20} value had been obtained and the measurements made at baseline repeated.

MEASUREMENTS
Heart rate, oxygen saturation, inspired and expired oxygen and carbon dioxide levels
Heart rate and oxygen saturation were measured using a pulse oximetry probe (Datex Division of Instrumentarium Corp, Helsinki, Finland). A side port on the face mask allowed continuous sampling of the inspired and expired gases and monitoring of respiratory rate. The gases were analysed using an OSCARoxy TM multigas monitor (Datex Instrumentarium Corp, Helsinki, Finland). Recordings were made every 10 seconds for one minute and automatically printed by a Hewlett Packard Think Jet printer in a blind fashion. Results were analysed after completion of the study.

FEV₁, FEV₁ was measured using a dry wedge spirometer (Vitalograph S, Vitalograph, Buckingham, UK) and the best of three attempts was taken for analysis.

Methacholine inhalation challenge
Baseline FEV₁ was measured by taking the best of three recordings. Thereafter a saline inhalation was administered and then doubling doses of nebulised methacholine (acetyl-β-methylcholine chloride (Sigma Chemical Company, Dorset UK) made up in normal saline) were administered at five minute intervals. Each concentration was given for two minutes via a MicroCirrus nebuliser. All challenge tests were performed by the same person throughout both studies. The nebuliser output for both gases in study 1 at a flow rate of 7 l/min was 0.13 ml/min, and in study 2 at a flow rate of 6 l/min the nebuliser output was 0.12 ml/min for both gases. The FEV₁ was measured at 0.5, 1.5, and three minutes after each inhalation until a fall in FEV₁ of at least 20% was achieved as determined by linear interpolation from the logarithmic dose-response curve. This result was then expressed as the methacholine PC_{20}.

All methacholine solutions were made up by the sterile unit of our pharmacy department.

Oxygen breathing circuit
All gases were administered from J size cylinders (3200 litre capacity, British Oxygen Corporation Medical Gases) via a calibrated flow head and a five litre rebreathing bag. The rebreathing bag was connected to an aircraft face mask (Thomas Respiratory Systems, London) via elephant tubing and a two way breathing valve.

Plasma catecholamines
Five millilitre aliquots of venous blood were collected into lithium heparin tubes, stored on ice, and spun within 90 minutes. Adrenaline and noradrenaline were later measured by radioenzymatic assay⁶ with both interassay and intra-assay variations of less than 10%.

STATISTICAL ANALYSIS
Statistical analysis was performed on an Apple Mackintosh LC II computer using a Statview software package (Brainpower Inc, Calabasas). Data were analysed for treatment, period and order effects as a two period crossover clinical trial using the method described by Hills and Armitage.⁷ The PC_{20} values were logarithmically transformed before analysis. A p value of <0.05 was accepted as significant.

Results
There were no significant differences in baseline measurements between study days in either study (table 2). Analysis for period and order effects showed no significant differences for any measurements.
Table 2  Mean (SE) baseline respiratory rate, heart rate and plasma catecholamine levels for patients in study 1 (hypoxia versus normoxia, n = 11) and study 2 (hyperoxia versus normoxia, n = 14)

<table>
<thead>
<tr>
<th>Baseline measurement</th>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normoxia</td>
<td>Hypoxia</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>2.67 (0.14)</td>
<td>2.63 (0.16)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>71.0 (4.0)</td>
<td>71.0 (4.7)</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>15.0 (1.5)</td>
<td>16.0 (1.6)</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>96.5 (0.2)</td>
<td>96.3 (0.2)</td>
</tr>
<tr>
<td>Inspired O2 (%)</td>
<td>20.8 (0.2)</td>
<td>21.0 (0.0)</td>
</tr>
<tr>
<td>End tidal CO2 (%)</td>
<td>4.66 (0.11)</td>
<td>4.64 (0.14)</td>
</tr>
<tr>
<td>Plasma noradrenaline (nmol/l)</td>
<td>1.72 (0.14)</td>
<td>1.61 (0.29)</td>
</tr>
<tr>
<td>Plasma adrenaline (nmol/l)</td>
<td>0.10 (0.02)</td>
<td>0.10 (0.02)</td>
</tr>
</tbody>
</table>

FEV1, = forced expiratory volume in one second. No significant differences were found between study days in either study.

STUDY 1

Methacholine PC20 values

The geometric mean PC20 methacholine value was significantly lower (p<0.05) on the hypoxic study day than on the normoxic day (fig 1A) with a mean difference between the hypoxic and normoxic study days of 2.88 mg/ml (95% CI 1.40 to 5.3).

Oxygen saturation

Oxygen saturation was significantly lower (p<0.01) following hypoxia (mean (SE) S\textsubscript{ao2} % at baseline 96.3 (0.24)%, pre-methacholine 91.0 (0.56)%, post-methacholine 90.5 (1.0)%) than following normoxia (mean (SE) S\textsubscript{ao2} % at baseline 96.5 (0.16)%, pre-methacholine 96.3 (0.27)%, post-methacholine 96.0 (0.43)%; fig 2A).

Heart rate

There was no significant difference in heart rate when the hypoxia and normoxia study days were compared at any time point (data not shown).

Oxyf

FEV1 after 10 minutes breathing the hypoxic gas mixture alone prior to inhalation of methacholine was not significantly different from on the normoxic study day (mean (SE) 2.40 (0.15) l following hypoxia and 2.38 (0.14) l on the normoxic study day).

STUDY 2

Methacholine PC20 values

There was no significant difference in the geometric mean PC20 methacholine values between the normoxic and hyperoxic study days (fig 1B), the mean difference being 1.45 mg/ml (95% CI 0.83 to 2.51).

Oxygen saturation

Oxygen saturation was significantly higher (p<0.01) following hypoxia (mean (SE) S\textsubscript{ao2} % at baseline 96.7 (0.35)%, pre-methacholine 98.1 (0.23)%, post-methacholine 98.1 (0.20)%) than during the normoxic study day (mean (SE) S\textsubscript{ao2} % at baseline 96.5 (0.33)%, pre-methacholine 96.7 (0.37)%, post-methacholine 96.0 (0.52)%; fig 2B).

Heart rate

The heart rate was significantly lower (p<0.05) on the hyperoxic study day both before and after the methacholine inhalation test than on the normoxic study day. The mean (SE) heart rate on the hyperoxic study day was: baseline 75 (4) bpm, pre-methacholine 71 (4) bpm, post-methacholine 71 (4) bpm and on the normoxic study day: baseline 77 (4) bpm, pre-methacholine 75 (5) bpm, post-methacholine 77 (4) bpm.

There were no significant differences in respiratory rate, percentage end tidal carbon di-

Figure 1  Effect of (A) hypoxia and normoxia (n = 11) and (B) hyperoxia and normoxia (n = 14) on PC20 methacholine values in patients with asthma.
Table 3  Mean (SE) respiratory rate, end tidal carbon dioxide (%) and plasma catecholamine levels following methacholine inhalation in study 1 (hypoxia versus normoxia, n=11) and study 2 (hyperoxia versus normoxia, n=14)

<table>
<thead>
<tr>
<th>Measurement after methacholine inhalation</th>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normoxia</td>
<td>Hypoxia</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>15.0 (1.6)</td>
<td>14.0 (2.0)</td>
</tr>
<tr>
<td>End tidal CO2 (%)</td>
<td>3.70 (0.18)</td>
<td>3.86 (0.17)</td>
</tr>
<tr>
<td>Plasma noradrenaline (nmol/l)</td>
<td>1.60 (0.16)</td>
<td>1.40 (0.25)</td>
</tr>
<tr>
<td>Plasma adrenaline (nmol/l)</td>
<td>0.08 (0.02)</td>
<td>0.06 (0.02)</td>
</tr>
</tbody>
</table>

No significant differences were found between study days in either study.

Discussion
We found that acute hypoxia (FiO2 0.15) potentiated methacholine induced bronchoconstriction in asthma whereas acute hyperoxia (FiO2 1.0) had no effect.

The changes in oxygen saturation we observed in both studies and the fall in heart rate seen on the hypoxic study day would suggest that our closed breathing circuit has achieved significant alterations in vascular oxygen tension. Both hypoxia and hyperoxia in vivo may cause a rise in minute ventilation and subsequent fall in end tidal carbon dioxide levels. Hypocapnia in vivo is associated with increased airway tone. We have shown no significant difference in percentage end tidal carbon dioxide levels between study days which suggests that an increase in airway tone due to hypocapnia has not influenced our results. Nebuliser output may be affected by the molecular weight of the gas used to drive the nebuliser. Before both studies the nebuliser output was calculated on two occasions for each study gas. In study 1 the nebuliser output for both air (FiO2 0.21) and the hypoxic gas mixture (FiO2 0.15) was 0.13 ml/min at a flow rate of 7 l/min and in study 2 the output for air (FiO2 0.21) and hyperoxia (FiO2 1.0) was 0.12 ml/min at 6 l/min. Circulating catecholamines have effects on airway smooth muscle tone. Any alteration in circulating levels of catecholamines due to changes in oxygen tension and inhalation of methacholine could potentially alter airway reactivity to methacholine. We have not, however, observed any significant differences in circulating catecholamine levels in either study.

Our double blind study has demonstrated an increase in airway reactivity to methacholine following acute hypoxia, in keeping with a previous single blind study reported by Denjean et al. Previous animal studies have suggested that the potentiation of methacholine induced bronchoconstriction by hypoxia is attenuated by prior surgical chemodenervation, suggesting that the effect is mediated via peripheral chemoreceptors. This does not, however, explain why potentiation of methacholine constriction by hypoxia in bovine bronchial rings is observed in vitro in the absence of circulating humoral factors and neural innervation. In our study we have been unable to detect an increase in airway tone following 10 minutes of hypoxia as one would expect if this effect occurred as a consequence of bronchoconstriction due to hypoxia alone. Other animal studies have shown that potentiation of histamine and carbachol induced bronchoconstriction in sheep is significantly reduced by both intravenous cromolyn sodium and FPL57231, a leukotriene receptor antagonist, suggesting that alveolar hypoxia may stimulate release of inflammatory mediators. Hypoxia may also act directly on smooth muscle cells, altering signal transduction pathways and causing smooth muscle contraction, or it may act on vagal nerve endings to stimulate neurotransmitter release and hence cause bronchoconstriction. These findings are likely to have clinical relevance as the level of hypoxia we have induced is compatible with those seen in patients admitted to hospital with acute severe exacerbations of...
Effect of alterations in inspired oxygen tension on methacholine induced bronchoconstriction


7. O’Cain CF, Hensley MJ, McFadden ER, Ingram RH. Pat-Six of their patients had arterial oxygen tensions below 10 kPa in keeping with resting hypoxaemia and, since inspiring 30% oxygen relieved hypoxic bronchoconstriction, this effect may have falsely influenced their results.


This study was supported by a grant from the British Lung Foundation. We also acknowledge the support of Mr Gordon Burnside of the Department of Medical Physics.
Effect of acute alterations in inspired oxygen tension on methacholine induced bronchoconstriction in patients with asthma.
K D Dagg, L J Thomson, R A Clayton, S G Ramsay and N C Thomson

Thorax 1997 52: 453-457
doi: 10.1136/thx.52.5.453